1 Introduction
2 Methods
2.1 Design
2.2 Patients
2.3 Procedures
2.4 Echocardiography
2.5 Neurohormonal markers
2.6 Statistical analysis
3 Results
Eprosartan | Control | p-value | |
---|---|---|---|
N = 47 | N = 50 | ||
Mean age (years±SD) | 65.2 (±9.7) | 63.9 (±9.7) | 0.52 |
% Female | 30 (65%) | 31 (62%) | 0.74 |
Body mass index | 28.7 (±4.2) | 29.2 (±5.3) | 0.63 |
Heart failure | 11 (23%) | 9 (18%) | 0.51 |
Current smoking | 8 (17%) | 8 (16%) | 0.89 |
Diabetes | 5 (11%) | 6 (12.0%) | 0.51 |
History of AMI | 0 (0%) | 2 (4%) | 0.17 |
NT-proBNP (pg/ml) | 113 (±101) | 125 (±139) | 0.63 |
Creatinin (μmol/L) | 84 (±20.8) | 80 (±20.6) | 0.52 |
eGFR (sMDRD) ml/min/1.73 m2
| 73.5 (±16.0) | 78.6 (±16.6) | 0.13 |
Cholesterol (mmol/l) | 5.2 (±1.2) | 5.2 (±1.0) | 0.14 |
baseline | 6 months | |||||
---|---|---|---|---|---|---|
Eprosartan (n = 47) | Control (n = 50) | p-value | Eprosartan (n = 45) | Control (n = 47) | p-value | |
ACE-inhibitor | 19 (40%) | 24 (48%) | 0.45 | 12 (27%) | 24 (51%) | 0.02 |
Betablocker | 17 (36%) | 18 (36%) | 0.97 | 17 (39%) | 24 (51%) | 0.23 |
Calcium-antagonist | 9 (19%) | 9 (18%) | 0.92 | 11 (24%) | 18 (38%) | 0.15 |
Diuretic | 12 (26%) | 18 (36%) | 0.26 | 20 (44%) | 31 (66%) | 0.04 |
3.1 Blood pressure changes
3.2 Echocardiographic changes
Eprosartan | Control | p-value between groups at 6 months | |||
---|---|---|---|---|---|
Baseline | 6 months | Baseline | 6 months | ||
E/A ratio | 0.85 (±0.26) | 0.85 (±0.17) | 0.84 (±0.21) | 0.93 (±0.26) | 0.09 |
DC time (ms) | 238 (±48) | 240 (±58) | 246 (±60) | 221 (±50) | 0.83 |
IVRT (ms) | 102 (±24) | 99 (±21) | 103 (±27) | 103 (±24) | 0.39 |
Mean E′(cm/s) | 8.0 (±2.3) | 8.3 (±2.2) | 8.4 (±2.1) | 8.5 (±2.0) | 0.48 |
LVMI (g/m2) | 110 (±37) | 102 (±36) | 106 (±27) | 110 (±27) | 0.31 |
RWT (mm) | 0.44 (±0.10) | 0.43 (±0.12) | 0.46 (±0.12) | 0.45 (±0.14) | 0.47 |
E/E′ | 9.3 (±4.0) | 9.4 (±4.2) | 8.7 (±2.5) | 8.9 (±3.5) | 0.50 |
LA diameter | 38 (±4.5) | 38 (±4.7) | 38 (±5.1) | 38 (±5.3) | 0.54 |
LVEF (%) | 58.0 (±4.2) | 58.0 (±3.5) | 58.4 (±3.1) | 57.6 (±5.4) | 0.69 |
Septal wall (mm) | 10.5 (±2.9) | 10.5 (±2.4) | 10.6 (±1.8) | 10.7 (±2.0) | 0.62 |
Posterior wall (mm) | 10.1 (±1.6) | 10.5 (±4.2) | 10.3 (±1.6) | 10.2 (±1.5) | 0.65 |
LVEDD (mm) | 47.8 (±4.9) | 45.4 (±9.3) | 46.3 (±5.8) | 47.4 (±7.0) | 0.26 |
LVESD (mm) | 29.6 (±6.2) | 28.3 (±7.5) | 30.0 (±4.5) | 26.1 (±7.5) | 0.17 |
PVa (cm/sec) | 32.4 (±6.3) | 33.5 (±13.0) | 33.2 (±10.3) | 32.0 (±12.9) | 0.59 |
3.3 Changes in neurohormonal markers
Baseline | 6 months | Change | ||||||
---|---|---|---|---|---|---|---|---|
Eprosartan | Control | Eprosartan | Control | p-value | Eprosartan | Control | p-value | |
NT-proBNP | 113 (±101) | 125 (±139) | 134 (±144) | 103 (±92) | 0.25 | +21 (±98) | −23 (±110) | 0.06 |
Aldosterone | 274 (±158) | 294 (±210) | 227 (±151) | 298 (±169) | 0.04 | −45 (±130) | −5 (±193) | 0.26 |
Renin | 15 (±11) | 54 (±120) | 15 (±8) | 14 (±12) | 0.26 | +7 (±6) | +5 (±10) | 0.72 |
ACE | 26 (±15) | 32 (±20) | 30 (±16) | 31 (±23) | 0.76 | +2 (±12) | −1 (±9) | 0.32 |